Development and validation of spectrophotometric method for simultaneous estimation of Sumatriptan and Naproxen sodium in tablet dosage form

Sumatriptan and Naproxen sodium in combined dosage form is used for the treatment of Migraine. Two new simple UV spectrophotometric methods have been developed and validated for the simultaneous determination of Sumatriptan (SUM) and Naproxen sodium (NAP) in their combined dosage forms. First method is QıAbsorption Ratio Method using two wavelengths, 272 nm (λmax of NAP) and 284 nm (Isoabsorptive point). The second method is the First order derivative technique. In this method the zero crossing point of Naproxen sodium was selected at 298 nm and for Sumatriptan it was 335 nm. The solvent used was methanol in both the above mentioned methods. The linearity range for QıAbsorption Ratio was 10- 90 μg/mL and for derivative method it was 20-190 μg/mL. All methods were validated statistically and recovery studies were carried out. All methods were found to be accurate, precise and reproducible. These methods were applied to the assay of the drugs in marketed formulation, which were found in the range of 98.0% to 102.0% of the labeled value for both Sumatriptan and Naproxen sodium. Hence, the methods herein described can be successfully applied in quality control of combined pharmaceutical dosage forms.

Author(s): Trinath. M, Saurabh K. Banerjee, Hari Hara Teja. D and C. G. Bonde

Abstract | PDF

Share This Article